Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-2.69%
1,068.24
-29.57
-2.69%
—1,097.811,087.761,087.761,067.42——
SIXC
Communications
SIXC
Communications
SIXC
-0.89%
606.59
-5.44
-0.89%
—612.03612.03612.03606.13——
SIXE
Energy
SIXE
Energy
SIXE
+2.19%
1,247.21
+26.78
+2.19%
—1,220.431,221.991,247.601,221.99——
SIXI
Industrials
SIXI
Industrials
SIXI
-1.82%
1,727.58
-31.94
-1.82%
—1,759.521,754.311,754.311,723.60——
SIXM
Financials
SIXM
Financials
SIXM
-0.32%
629.54
-2.00
-0.32%
—631.54631.27633.99628.63——
SIXR
Staples
SIXR
Staples
SIXR
-0.42%
853.60
-3.56
-0.42%
—857.16858.91861.71852.33——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-1.56%
212.04
-3.37
-1.56%
—215.41215.41215.41211.88——
SIXT
Technology
SIXT
Technology
SIXT
-1.78%
3,549.76
-64.39
-1.78%
—3,614.153,556.243,598.363,516.86——
SIXU
Utilities
SIXU
Utilities
SIXU
-2.40%
886.49
-21.81
-2.40%
—908.30906.55906.55885.88——
SIXV
Health care
SIXV
Health care
SIXV
-1.08%
1,464.34
-16.06
-1.08%
—1,480.401,479.551,484.431,462.52——
SIXY
Discretionary
SIXY
Discretionary
SIXY
-1.84%
2,354.25
-44.12
-1.84%
—2,398.372,373.092,373.092,350.27——
CAMX:STO
Camurus AB
SEK 509.50
+2.52%
(+12.50) 1D
May 15, 5:29:38 PM GMT+2  ·   SEK
All symbols
SymbolPriceChange% Change
Generating top insights for CAMX...
Open
SEK 524.00
High
SEK 528.50
Low
SEK 508.00
Mkt. cap
30.83B
Avg. vol.
94.34K
Volume
111.99K
52-wk high
SEK 754.50
52-wk low
SEK 430.80
Shares outstanding
59.99M
No. of employees
308
News stories
From sources across the web
Profile
Camurus AB is a Swedish research-based pharmaceutical and biotechnology company specialising in the commercialization of medicines for treating serious and chronic diseases. Established in 1991 and based in the southern university city of Lund, in the Medicon Valley region, the company is listed on Nasdaq Stockholm, Mid Cap. Camurus was founded by scientists in biophysical, food, and pharmaceutical chemistry with expertise in lipid phase structures. The company provides nanoscale drug-delivery systems for development of high-value therapeutics. Wikipedia
About Camurus AB
CEOFredrik Tiberg
Employees308
Founded1991
Headquarters-
SectorPharmaceutical industry
Websitecamurus.com
Previous reportsAll values in SEK
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in SEK
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
675.50M
567.07M
464.46M
533.10M
Cost of goods sold
41.14M
39.33M
36.38M
37.16M
Cost of revenue
41.14M
39.33M
36.38M
37.16M
Research and development expenses
151.19M
109.34M
124.94M
137.61M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
185.12M
181.13M
184.49M
177.48M
Operating expense
342.31M
297.52M
304.07M
327.54M
Total operating expenses
383.45M
336.85M
340.45M
364.70M
Operating income
292.05M
230.22M
124.01M
168.40M
Other non operating income
-
-
-17.00K
16.93M
EBT including unusual items
307.01M
245.28M
126.84M
183.86M
EBT excluding unusual items
307.01M
245.28M
126.80M
183.86M
Income tax expense
62.22M
52.64M
25.96M
40.04M
Effective tax rate
20.27%
21.46%
20.47%
21.78%
Other operating expenses
6.00M
7.05M
-5.36M
12.45M
Net income
244.79M
192.64M
100.88M
143.82M
Net profit margin
36.24%
33.97%
21.72%
26.98%
Earnings per share
4.08
3.19
1.67
2.40
Interest and investment income
16.38M
16.50M
15.54M
-
Interest expense
-1.42M
-1.44M
-1.46M
-1.47M
Net interest expenses
14.96M
15.06M
14.08M
-1.47M
Depreciation and amortization charges
-
-
-
-
EBITDA
298.33M
236.64M
130.67M
169.84M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer